Skip to main content
NewslettersWatchlist

Eli Lilly and Company(LLY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low749.52
Day High768.00
Open:760.07
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Motley Fool
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Motley Fool
3 Magnificent Stocks That Could Double or More by 2030
Motley Fool
This Vanguard ETF Has Skyrocketed 40% in 12 Months. Is It a No-Brainer Buy Right Now?
Motley Fool
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Motley Fool
Why Roche Holdings Stock Popped Today
Motley Fool
The Next "Magnificent Seven"?
Elliott Wave Forecast
LLY Should Provide Opportunity In Few Weeks
Motley Fool
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Motley Fool
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Barchart
This Small-Cap Biotech Could Gain Over 165%, Says Wall Street
Motley Fool
2 Growth Stocks to Buy Hand Over Fist in April
Motley Fool
This 1 Number May Ensure Eli Lilly's Dominance in the Weight Loss Drug Market
Motley Fool
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Barchart
1 Future Dividend Aristocrat to Buy Now
Motley Fool
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
Motley Fool
Is it Too Late to Buy Viking Therapeutics Stock?
Motley Fool
Here's the Artificial Intelligence (AI) Stock I Think Will Be the Next to Join Microsoft, Apple, Nvidia, Alphabet, Amazon, and Meta in the $1 Trillion Club
Barchart
Down 32% in a Year, Should Investors Buy the Dip in Pfizer Stock?
Motley Fool
Viking Therapeutics Just Announced More Positive Results: Time to Buy?
Motley Fool
After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
Motley Fool
1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now
Motley Fool
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
Motley Fool
Why Eli Lilly Stock Topped the Market Today
Barchart
Stocks Rebound on a Dovish US ISM Services Report
Barchart
Stocks Waver on Higher Bond Yields Ahead of Fed Chair Powell
Motley Fool
Could Viking Therapeutics Stock Be a Millionaire Maker?
Motley Fool
Is It Too Late to Buy Eli Lilly Stock?
Motley Fool
Viking Therapeutics Stock Has 72% Upside, According to 1 Wall Street Analyst
Motley Fool
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
Motley Fool
Meet The "Magnificent Seven" of Healthcare Stocks

Profile

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.